Nav: Home

Moffitt identifies novel therapeutic targets in cutaneous squamous cell carcinoma

March 30, 2020

TAMPA, Fla. - Cutaneous squamous cell carcinoma (cuSCC) is the second most common diagnosed malignancy in the United States, with approximately 700,000 new cases each year. Cumulative exposure to ultraviolet light is the primary environmental risk factor that leads to cuSCC. While the majority of cuSCC cases are easily managed and treated, a small percentage of patients do not respond to treatment and have poor outcomes. Researchers at Moffitt Cancer Center want to devise better therapeutic strategies for this patient population by improving their understanding of how cuSCC develops. In a new article published online ahead of print in the journal Cancer Research, Moffitt scientists report on their identification of potential therapeutic targets for cuSCC.

The Flores Lab has been focused on identifying therapeutic targets for p53 mutant cancers. In this research, the team focused on the activity of the protein TAp63 - a tumor suppressor protein that is part of the p53 family of tumor suppressors. This family of proteins normally function to inhibit tumor development and growth. TAp63 is also known to compensate for p53 loss and to play an important role in the creation of small segments of RNA called microRNAs that are present in the human genome. MicroRNAs contribute to many biological processes and are often deregulated in different diseases, including cancer.

The researchers wanted to determine whether the ability of TAp63 to function as a tumor suppressor and regulator of microRNAs could impact the development of cuSCC. They treated mice that were missing the TAp63 gene and normal mice with ultraviolet light and discovered that mice without the TAp63 gene developed a significantly higher number of cuSCCs than normal mice. These observations demonstrate that TAp63 also acts as a tumor suppresser protein in the skin.

Flores's team then performed a series of comparative studies in both mouse and human cuSCC tumor samples and discovered that two microRNAs - miR-30c-2* and miR-497 - were expressed at much lower levels in tumors that lacked TAp63. When these microRNAs were reintroduced into tumor cells, the development of cuSCCs was significantly reduced. These observations suggest that miR-30c-2* and miR-497, similar to TAp63, may function by inhibiting the growth and development of cuSCC. The researchers verified this hypothesis by showing that miR-30c-2* contributes to cell death, while miR-497 inhibits cell growth and proliferation; therefore, when these miRNAs are missing, cuSCC growth can proceed unchecked.

The team also performed studies to assess how downstream targets of the microRNAs impacted cuSCC growth. They demonstrated that seven genes that are targets of the microRNAs are commonly deregulated in cuSCC tumors, including the AURKA gene. They confirmed the importance of AURKA by showing that inhibition of AURKA was able to reduce cuSCC growth in mouse models, suggesting that AURKA may be an appropriate therapeutic target.

"Our study establishes TAp63 as an essential suppressor of UV-induced cuSCC and reveals a previously undescribed functional network of microRNAs and targeted mRNAs," said Elsa Flores, Ph.D., chair of Moffitt's Department of Molecular Oncology and leader of the Cancer Biology and Evolution Program. "Given the lack of FDA approved targeted therapies for advanced cuSCC, our study provides preclinical evidence for the use of miR-30c-2*/miR-497 delivery or AURKA inhibition for the effective treatment approach."

Flores hopes this will lead to further investigations on these potential targets.
-end-
This study was partially supported by a National Cancer Institute Outstanding Investigator Award given to Flores.

About Moffitt Cancer Center

Moffitt is dedicated to one lifesaving mission: to contribute to the prevention and cure of cancer. The Tampa-based facility is one of only 51 National Cancer Institute-designated Comprehensive Cancer Centers, a distinction that recognizes Moffitt's scientific excellence, multidisciplinary research, and robust training and education. Moffitt is a Top 10 cancer hospital and has been nationally ranked by U.S. News & World Report since 1999. Moffitt's expert nursing staff is recognized by the American Nurses Credentialing Center with Magnet® status, its highest distinction. With more than 6,500 team members, Moffitt has an economic impact in the state of $2.4 billion. For more information, call 1-888-MOFFITT (1-888-663-3488), visit MOFFITT.org, and follow the momentum on Facebook, Twitter, Instagram and YouTube.

H. Lee Moffitt Cancer Center & Research Institute

Related Tumor Suppressor Articles:

New results on the function of the tumor suppressor HERC protein
The RAF protein could be a therapeutical target to treat the tumor growth in regulated pathways by the p38 protein, according to a new study published in the journal Scientific Reports by a team of experts of the Faculty of Medicine and Health Sciences of the University of Barcelona and the Bellvitge Institute for Biomedical Research (IDIBELL).
New function for potential tumor suppressor in brain development
New research from the group of Simon Hippenmeyer, professor at the Institute of Science and Technology Austria (IST Austria), has now uncovered a novel, opposite role for Cdkn1c.
Researchers determine how a major tumor suppressor pathway becomes deactivated
The Hippo pathway is an important biological tumor suppressor program that controls cell growth and organ size in humans.
Nanoparticle therapeutic restores function of tumor suppressor in prostate cancer
Leveraging advances in mRNA and nanotechnology, investigators demonstrate that tumor suppressor PTEN can be restored in preclinical models of prostate cancer.
Discovery of a new tumor suppressor previously thought to be an oncogene
A gene that has for decades been considered a tumor promoter, the PLK1 gene, can also perform the exact opposite function: halting the development of cancer.
Unraveling role of tumor suppressor in gene expression & ovarian tumorigenesis
The tumor suppressor protein ARID1A controls global transcription in ovarian epithelial cells, according to new research conducted at The Wistar Institute, which provided mechanistic insight into tumorigenesis mediated by ARID1A loss in ovarian cancer.
Tumor suppressor protein plays key role in suppressing infections
Researchers have found that a previously uncharacterized tumor-suppressor protein plays an important role in the functioning of the immune system.
Tumor suppressor protein targets liver cancer
Salk Institute scientists, together with researchers from Switzerland's University of Basel and University Hospital Basel, discovered a protein called LHPP that acts as a molecular switch to turn off the uncontrolled growth of cells in liver cancer.
Stanford-led study uncovers mutation that supercharges tumor-suppressor
Stanford scientists have found an answer to one of cancer biology's toughest and most important questions: how does the body suppress tumors?
Injecting activator of a powerful tumor suppressor directly into the cancer increases tumor destruction, decreases toxicity
Directly injecting a tumor with an agent that activates a natural, powerful tumor suppressor enhances the drug's capacity to attack the tumor both locally and where it spreads, scientists report in the journal Cancer Research.
More Tumor Suppressor News and Tumor Suppressor Current Events

Trending Science News

Current Coronavirus (COVID-19) News

Top Science Podcasts

We have hand picked the top science podcasts of 2020.
Now Playing: TED Radio Hour

Listen Again: IRL Online
Original broadcast date: March 20, 2020. Our online lives are now entirely interwoven with our real lives. But the laws that govern real life don't apply online. This hour, TED speakers explore rules to navigate this vast virtual space.
Now Playing: Science for the People

#574 State of the Heart
This week we focus on heart disease, heart failure, what blood pressure is and why it's bad when it's high. Host Rachelle Saunders talks with physician, clinical researcher, and writer Haider Warraich about his book "State of the Heart: Exploring the History, Science, and Future of Cardiac Disease" and the ails of our hearts.
Now Playing: Radiolab

Falling
There are so many ways to fall–in love, asleep, even flat on your face. This hour, Radiolab dives into stories of great falls.  We jump into a black hole, take a trip over Niagara Falls, upend some myths about falling cats, and plunge into our favorite songs about falling. Support Radiolab by becoming a member today at Radiolab.org/donate.